Edesa Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>EB</div>
EDSA -- USA Stock  

USD 8.20  0.14  1.74%

Despite somewhat weak basic indicators, Edesa Biotech sustained solid returns over the last few months and may actually be approaching a breakup point. The company almost mirrors the market. We can now analyze Edesa as a potential investment option for your portfolios.
Published over three weeks ago
View all stories for Edesa Biotech | View All Stories
Does Edesa Biotech (NASDAQ:EDSA) have strong basic indicators based on the current rise?
We provide trade advice to complement the prevailing expert consensus on Edesa Biotech. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. Edesa Biotech dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Edesa Biotech income statement, its balance sheet, and the statement of cash flows. Potential Edesa Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Edesa Biotech investors may use each financial statement separately, they are all related. The changes in Edesa Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Edesa Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Edesa Biotech fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Edesa Biotech performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Edesa Biotech shares is the value that is considered the true value of the share. If the intrinsic value Edesa is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Edesa Biotech. Please read more on our fundamental analysis page.

Are Edesa Biotech Earnings Expected to grow?

The future earnings power of Edesa Biotech involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Edesa Biotech factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Edesa Biotech stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Edesa expected earnings.

How Edesa utilizes its cash?

To perform a cash flow analysis of Edesa Biotech, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Edesa Biotech is receiving and how much cash it distributes out in a given period. The Edesa Biotech cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Edesa Biotech Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (1.48 Million)

Edesa Biotech Gross Profit

Edesa Biotech Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Edesa Biotech previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Edesa Biotech Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Edesa Biotech exotic insider transaction detected

Legal trades by Edesa Biotech insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Edesa insider trading alert for general transaction of common shares by Nijhawan Pardeep, Chief Executive Officer, on 18th of September 2020. This event was filed by Edesa Biotech Inc with SEC on 2020-09-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Edesa Biotech Indicators

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Edesa Biotech is not uncomon. Many companies such as Edesa Biotech have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of Edesa is distributed among investors.

Ownership Allocation

Edesa Biotech retains a total of 9.41 Million outstanding shares. Edesa Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
Retail Investors28.34

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Edesa Biotech has an asset utilization ratio of 11.46 percent. This suggests that the company is making $0.11 for each dollar of assets. An increasing asset utilization means that Edesa Biotech is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
5.8 M
Current Assets5.82 Million97.93
Assets Non Current6,822.330.11

Another 3 percent rise for Edesa Biotech

Current downside deviation is at 7.21. As of the 30th of August, Edesa Biotech shows the Mean Deviation of 7.64, coefficient of variation of 848.94, and Downside Deviation of 7.21. Edesa Biotech technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Edesa Biotech, which can be compared to its rivals. Please confirm Edesa Biotech coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Edesa Biotech is priced favorably, providing market reflects its regular price of 8.15 per share. Given that Edesa Biotech has jensen alpha of 2.08, we urge you to verify Edesa Biotech's prevailing market performance to make sure the company can sustain itself at a future point.

The Current Takeaway on Edesa Biotech Investment

Whereas some other companies under the biotechnology industry are still a bit expensive, Edesa Biotech may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Edesa Biotech.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Edesa Biotech. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com